The FDA has approved Crysvita (burosumab-twza) injection to treat patients age two and older with tumor-induced osteomalacia (TIO), a rare disease that is characterized by the development of tumors that cause weakened and softened bones.
Read more: FDA Approves First Therapy for Rare Disease that Causes Low Phosphate Blood Levels, Bone Softening